BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
ATLANTA, March 03, 2017 -- Alimera Sciences (NASDAQ:ALIM), a leader in the commercialization, research and development of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the 37th Annual Cowen Health Care Conference, to be held March 6-8, 2017 at The Boston Marriott Copley Place, Boston, Massachusetts. Alimera Sciences' presentation will take place Monday, March 6, 2017, at 4:40 PM Eastern Time.
A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of the Company's website at www.alimeraciences.com. A replay of the conference presentation will also be available.
About Alimera Sciences
Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the commercialization, research and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
Contact: CG Capital 877.889.1972 [email protected] cg.capital
